Tayebeh Farhadi - Department of Pharmaceutical Biotechnology, School of Pharmacy, Shiraz University of Medical Sciences,Shiraz, Iran Pharmaceutical Sciences Research Center, School of Pharmacy, Shiraz University of Medical Sciences,Shiraz, Iran
Zeinab Karimi - Department of Pharmaceutical Biotechnology, School of Pharmacy, Shiraz University of Medical Sciences,Shiraz, Iran Pharmaceutical Sciences Research Center, School of Pharmacy, Shiraz University of Medical Sciences,Shiraz, Iran
Younes Ghasemi - Department of Pharmaceutical Biotechnology, School of Pharmacy, Shiraz University of Medical Sciences,Shiraz, Iran Pharmaceutical Sciences Research Center, School of Pharmacy, Shiraz University of Medical Sciences,Shiraz, Iran
Navid Nezafat - Pharmaceutical Sciences Research Center, School of Pharmacy, Shiraz University of Medical Sciences,Shiraz, Iran

Klebsiella pneumoniae is a hospital-acquired pathogen that leads to various infections. Hence, efforts to develop an effective vaccine against that pathogen are well documented. Our interest is the production of the previously designed multi-epitope vaccine construct against the K. pneumoniae in a prokaryotic host. Therefore, a new construct containing the nucleotide sequence of the novel vaccine was successfully expressed in Escherichia coli and then purified by Ni-NTA spin column. The purified recombinant protein can be considered as potential vaccine candidate for wet-laboratory analysis aiming to fight K pneumoniae

Klebsiella pneumoniae, Multi-epitope vaccine, Vaccine production